Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


  • Sort by Product ID
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Lenvima

    Read More

    Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).

    September 9, 2019
    Find out more
  • Letairis

    Read More

    Letairis (ambrisentan; Gilead/AbbVie/GlaxoSmithKline) is a selective endothelin type A (ETA) receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory.

    October 29, 2018
    Find out more
  • Lupron

    Read More

    Lupron (leuprolide; Takeda/AbbVie) is a gonadotropin-releasing hormone (GnRH) agonist which acts on the pituitary gland in the brain to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”

    January 18, 2018
    Find out more
  • Actemra

    Read More

    Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.

    March 24, 2015
    Find out more
  • Activase

    Activase

    Read More

    Activase (alteplase; Roche/Boehringer Ingelheim/Kyowa Hakko Kirin) is a recombinant tissue plasminogen activator, and is a manufactured version of the tissue plasminogen activating proteins found naturally in endothelial cells.

    July 2, 2018
    Find out more
  • Adempas

    Read More

    Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.

    October 29, 2018
    Find out more
  • omadacycline

    Read More

    Omadacycline (Paratek Pharmaceuticals) is the first agent of the aminomethycyclines class of antibiotics. The drug, which is a semisynthetic derivative of the tetracycline minocycline.

    June 19, 2015
    Find out more
  • Opsumit

    Read More

    Actelion’s Opsumit (macitentan) is the follow-on product to the leading pulmonary arterial hypertension (PAH) therapy Tracleer.

    October 29, 2018
    Find out more
  • Aggrenox

    Aggrenox

    Read More

    Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole.

    July 2, 2018
    Find out more
  • Orbactiv

    Read More

    Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis.

    September 10, 2014
    Find out more
  • orencia report

    Orencia

    Read More

    Orencia (abatacept; Bristol-Myers Squibb/Ono Pharmaceutical) is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte antigen-4.

    October 17, 2017
    Find out more
  • Orenitram

    Read More

    United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.

    October 19, 2018
    Find out more
  • Recentin

    Read More

    Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases.

    October 30, 2015
    Find out more
  • Remodulin

    Read More

    Remodulin (treprostinil; United Therapeutics/Antigen/Mochida) is a prostaglandin analog that functions as a prostaglandin I2 (PGI2) receptor agonist.

    October 29, 2018
    Find out more
  • Revatio

    Read More

    Revatio (sildenafil), manufactured by Pfizer, is a selective inhibitor of the phosphodiesterase 5 (PDE5) enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide (NO).

    October 29, 2018
    Find out more
Page 2 of 41
Page 2 of 41‹1234›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top